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Abstract 
Background: In persons with multiple sclerosis (MS) self‑efficacy positively affects health‑related quality of life 
(HRQoL) and physical activity. In a previous study we observed that 6 months after an intensive 3‑day social cognitive 
treatment (Can Do treatment) with the participation of support partners, self‑efficacy and HRQoL had improved in 
persons with relapsing remitting MS (RRMS). Given the chronic nature of the disease, it is important to know whether 
these beneficial changes may last.
Methods: Can Do treatment was given to 60 persons with MS and their support partners. At baseline and 12 months 
after treatment self‑efficacy control, self‑efficacy function, physical and mental HRQoL, anxiety, depression and fatigue 
were assessed via self‑report questionnaires. Differences were tested via a paired t test.
Results: Of the 57 persons with MS that completed the baseline assessment and the 3‑day treatment, 38 filled in the 
12th month questionnaires (response rate 66.7 %), 22 with RRMS and 14 with progressive MS. In the RR group self‑
efficacy control had increased by 20.2 % and physical HRQoL by 15.0 %, and depression and anxiety had decreased 
by 29.8 and 25.9 %, respectively (all P < 0.05); the changes in mental HRQoL (+17 %) and fatigue (−20 %) failed to 
be statistically significant (P = 0.087, P = 0.080, respectively). In the progressive group no changes suggestive of 
improvement were seen.
Conclusions: The findings suggest that a 3‑day intensive social cognitive treatment (Can Do treatment) with the 
participation of support partners may have long lasting beneficial effects on the self‑efficacy and HRQoL in persons 
with RRMS; and that improvements in anxiety and depression, not seen in the 6‑month study, may yet develop at 
12 months.
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Background
Multiple sclerosis (MS) is a chronic disease of the central 
nervous system pathologically characterized by immune-
mediated inflammation, demyelination and axonal 
degeneration. In most persons with MS the first symp-
toms occur between 20 and 45 years of age, and the initial 
course is characterized by relapses, followed by complete 
or incomplete recovery: relapsing-remitting MS (RRMS). 
The symptoms and disabilities are highly variable and 
unpredictable. Despite disease modifying treatment most 
people with RRMS convert to the secondary progressive 
phase (SPMS), for which no treatment is available. The 
response to disease modifying treatment in RRMS varies 
between persons and is difficult to prognosticate.
Self-efficacy is a psychological concept that refers to the 
degree in which a person is confident to complete tasks 
and reach goals in specific situations [1–3]. The belief in 
one’s ability to produce effects or outcomes one wants 
is a core component in social cognitive theory, in which 
psychosocial functioning is determined by reciprocal 
interactions between personal factors, behaviour, and the 
environment [1–3]. Self-efficacy is influenced by experi-
ence, social persuasion, and physiological factors [1–3]. 
Self-efficacy itself may affect human function in vari-
ous ways. First, by influencing choices regarding behav-
iour: people generally avoiding tasks where self-efficacy 
is low, but undertaking tasks where self-efficacy is high 
[4, 5]. Second, by affecting motivation: people with high 
self-efficacy are more likely to make efforts to complete a 
task, and to persist longer in those efforts, whereas those 
with low self-efficacy will tend toward discouragement 
and giving up [4–6]. Third, self-efficacy has effects on 
thought patterns and responses: low self-efficacy can lead 
people to believe tasks to be harder than they actually 
are, which often results in poor planning and increased 
stress [4, 5].
In chronic conditions the relationship between self-
efficacy and psychological well-being has been convinc-
ingly documented [3, 7]. Self-efficacy is also one of the 
most consistent determinants of physical activity across 
populations, including those with MS [8]. Most people 
with (PwMS) become increasingly disabled in the course 
of the disease, with disabilities negatively affecting their 
independence, and the negative experience of losing 
independence negatively affecting self-efficacy. In fact, 
MS is associated with a large reduction in physical activ-
ity behaviours, and evidence indicates that this reduction 
correlates with self-efficacy [9]. It has also been demon-
strated that in PwMS self-efficacy not only has a positive 
relationship with physical activity [10–12], but also with 
physical and psychological health-related quality of life 
(HRQoL) [13–15], and psychological adjustment [7]; and 
that it is negatively associated with depression [6].
Randomized controlled trials have shown that vari-
ous treatment modalities may improve self-efficacy in 
patients with chronic conditions. In persons with per-
sistent neck pain a multi-component self-management 
group intervention resulted in a 2-year improvement in 
pain-related self-efficacy [16], and in a 1-year study in 
patients with chronic low back pain both mindfulness-
based stress reduction and cognitive-behavioural therapy 
had a positive effect on self-efficacy [17]. In rheumatoid 
arthritis patients a 32-week study showed that needs-
based patient education did improve arthritis-related 
self-efficacy [18], and in older adults with osteoporosis 
balance training with multi-task exercises improved fall-
related self-efficacy in a 12-week study [19]. As far as 
MS is concerned, Rigby et al. [20] showed in a 12-month 
randomized controlled trial that group cognitive-behav-
ioural sessions supported by an information booklet, and 
non-structured social discussion sessions supported by 
an information booklet, both resulted in improved MS-
related self-efficacy.
In 2014 we reported the results of an observational 
study in PwMS on the effects of an intense, multidisci-
plinary, 3-day, social cognitive Can Do treatment pro-
gram with the participation of support partners [21]. The 
concept of the Can Do treatment is based on the biopsy-
chosocial model of somatisation, developed by Rosen, 
Kleinman and Katon [22], augmented by elements from 
clinical psychotherapy. According to the biopsycho-
social model, illness behaviours like somatic symptom 
presentation and medical help seeking occur in reaction 
to underlying life stressors, e.g. unemployment or mari-
tal conflict [22]. Physicians and the medical care system 
often play a significant role in reinforcing somatisation 
by patients [22]. The identification of individual stress-
ors and their elimination or mitigation are believed to 
result in decreased somatisation and help seeking, and 
in increased self-efficacy and autonomy. The supposedly 
therapeutic elements in the Can Do approach are group 
interactions, the accent on potentials instead on limita-
tions, the participation of the support partner, the neces-
sity to take initiatives and actions, obtaining information 
leading to adjustment of the self-image, the presence of 
a multi-disciplinary team guaranteeing that all aspects of 
living with a chronic diseases are considered, and every 
action depending on an explicit choice. Crucial to the 
Can Do treatment is that patients and their support part-
ners are continuously encouraged to make choices and to 
take action, and are thus stimulated to make optimal use 
of their self-efficacy.
We found that 6  months after Can Do treatment, 
relapsing remitting (RR) patients showed a 24.8  % 
increase in self-efficacy control (primary outcome) and 
22.3 and 17.6 % increases in mental and physical HRQoL 
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(secondary outcomes), respectively [21]. In contrast, 
progressive patients only showed an increase in men-
tal HRQoL by +11.5  % at 1  month. However, given the 
chronic, and as yet incurable, nature of the MS disease 
process, it is important to be informed on eventual 
improvements occurring after Can Do treatment in the 
longer term. Therefore, to explore whether the benefi-
cial changes seen at 6 months could also be observed at 
1  year we performed the present study. Here we report 
the results.
Methods
Can Do treatment
Concept
The Can Do treatment aims to uncover and promote 
existing capabilities, with the notion ‘stressor’ as central 
concept. The treatment is primarily a sociologically ori-
ented approach. It tries to identify stressors that confine 
PwMS to their physical, psychological or social roles. 
To reduce these stressors, the treatment is based on 
five principles: identification and reduction of existing 
stressors; client-centeredness; inclusion of the partner 
or another significant informal caregiver; group sessions; 
and self-reliance, autonomy, and acceptance as central 
themes. Accordingly, the Can Do treatment focuses on 
the exploration of stressors that confine PwMS to their 
disease and their limitations; reduces relevant stress-
ors; makes participants to explore and exceed their own 
boundaries; and creates new personal boundaries by 
optimally using the existing potential. To give the capa-
bilities of each individual a realistic framework the cen-
tral mottos are ‘Can’, ‘Will’, ‘Choose’, ‘Open up to others’, 
and ‘Do’. The treatment’s message is that by exploring 
their boundaries PwMS become more aware of their fac-
ulties and improve their self-management, which leads to 
a higher awareness of potentials and a better communi-
cation with health care professionals.
Components
The treatment includes (1) large group sessions, (2) small 
group sessions, (3) consultations, (4) a theatre evening, 
and (5) start of the day with a joint activity (optionally).
Large group sessions Plenary sessions in which the par-
ticipants make optimal use of their potentials, learn how 
to support and encourage each other, and experiment on 
how to give the required feedback to the multidiscipli-
nary team. Group sessions including half the participants 
in which the participants examine and identify the stress-
ors that have to be addressed most, and formulate realiz-
able individual aims (one or two).
Small group sessions The small group sessions form the 
actual treatment. Depending on the individual goals 
the participants sign up for the training groups ‘body’, 
‘feeling’ or ‘life’, to work out their aims and to experiment 
whether they can reduce their stressors. The body ses-
sions explore the physical capabilities and are coached by 
a physiotherapist. The feeling sessions explore the emo-
tional potential and are coached by a psychiatrist and a 
psychiatric nurse. The life sessions explore the capabili-
ties relating to the daily living with MS and are coached 
by a neurologist, a registered nurse specialized in MS, 
and a person with MS. Moreover, there are relaxation 
sessions: the Yoga session focusing on body experience 
and relaxation, and the Physical session focusing on 
relaxation through physical strain. Participants choose 
between the various small group sessions autonomously.
Consultations After having identified and formulated 
(large group sessions) the individual stressors and aims, 
the participants sign in for one or more group consulta-
tions, to verify whether their aims are realistic, by asking 
the team members for aim-related medical information.
Theater evening On the informal theater evening the 
participants practice to change roles and to show their 
potentials by openly experimenting. They do their best to 
perform before each other and the team. The collective 
performance increases the group cohesion and learns the 
participants to find an equilibrium between consuming 
and action.
Common activity at the start of the day During an 
optional common activity (walk in the woods) at the start 
of the day the participants experiment with physical chal-
lenges and with their energy management.
Multidisciplinary team
The multidisciplinary consisted of a psychiatrist, psy-
chiatric nurse, neurologist, MS Nurse, Physiotherapist, 
Yoga Teacher, and a person with MS. The team members 
stimulate, defy and confront the participants to explore 
and extend their boundaries. Apart from the consulta-
tions, the team keeps to coaching, motivating and acti-
vating the participants. By participating in all large group 
sessions the team members familiarize themselves with 
the participants’ stressors and goals. During the consulta-
tions they have a professional and informative role and in 
the small group sessions they focus on their own areas of 
interest. During a tip time at the end of the day the team 
members evaluate the sessions, inform each other on the 
participants’ progresses and obstacles, discuss whether 
the participants make optimal use of their capabilities, 
and monitor to what degree the individual goals are 
being attained.
Study design and organization
The study was exploratory and uncontrolled. The Can 
Do treatment was given during 3  days. Each treatment 
course was given to 10 PwMS and their significant support 
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partner (partner or informal caregiver). The inclusion cri-
teria were: diagnosis definite MS, relapse free in the last 
4 weeks, and able and willing to participate in the Can Do 
treatment and the study-related assessments. Data were 
obtained by the use of paper-and-pencil self-report ques-
tionnaires, sent by regular mail 1–4  weeks before and 
12 months after the treatment, accompanied by a stamped 
return envelope addressed to the MS4 Research Institute 
(groups 1 and 2; baseline assessment in groups 3–6) or by 
online versions of the questionnaires (month 12 assess-
ment in groups 3–6). As to the latter, after having given 
informed consent the patients received a personal code 
and logged on to the website of the MS4 Research Insti-
tute, to choose a username and password. The online 
assessments were performed using the LimeSurvey soft-
ware, an open source online application. There was no 
testing of the MS4 Research Institute’s platform for this 
study since it was already being used in various research 
projects. The items of the questionnaire were fixed. The 
responses were automatically captured. To protect the 
personal data from unauthorized access various mecha-
nisms were used to comply with European Union regula-
tions concerning online medical data, including the use of 
a personal username and a strong password, separation in 
the database of personal information from the answers to 
the questions, each screen having a username and pass-
word protection, VPN tunnelling, 256-bits encryption, and 
the encryption of the participants’ identities via unique 10 
digits codes. Automated completeness checks were done 
before questionnaires could be submitted. The respond-
ents saw an overview of all questions and answers before 
submission and they could change the answers before 
submitting. After submission changes were no longer pos-
sible. Only completed questionnaires were analyzed. The 
help desk (MH) contacted respondents by phone when 
they had not completed the questionnaires within 1 week 
after the scheduled date, in order to remind them.
Outcome measures
Primary outcomes measures
Self-efficacy was assessed by the multiple sclerosis self-
efficacy scale (MSSES) [23], which consists of two 9-item 
subscales of function and control. Each item is scored 
on a Likert-like scale form 10 (very uncertain) to 100 
(very certain) and addition of the respective item scores 
yields the MSSES function and control scores, both rang-
ing from 90 (minimum) to 900 (maximum). The MSSES 
function subscale measures confidence with functional 
abilities, whereas the MSSES control subscale measures 
confidence with managing symptoms and coping with 
the demands of illness [23].
The impact on participation and autonomy (IPA) ques-
tionnaire is a 32-item self-report instrument for the 
quantification of limitations in participation and auton-
omy in persons with chronic health conditions [24, 25]. 
The IPA Limitations subscale assesses perceived limita-
tions in participation and autonomy in relation to 32 dif-
ferent life situations across five subscales [24–26]. Items 
are rated on a 5-point scale from 0 (very good) to 4 (very 
poor), and a higher score indicates a higher limitation to 
participation and autonomy. The IPA Problems subscale 
examines the extent to which these limitations are expe-
rienced as problematic, by assessing nine different areas 
of participation and autonomy [24–26]. The perceived 
problems are graded on 3-point scale ranging from 0 (no 
problem) to 2 (severe problems), and a higher IPA Prob-
lems score indicates a greater experience of problems 
[24–26].
Secondary outcome measures
HRQoL was assessed by the Multiple Sclerosis Quality of 
Life 54-Items (MSQoL-54) questionnaire [27]. A physi-
cal and a mental dimension underlie the MSQoL-54: 
the Physical and Mental domains [27]. Scores for each 
domain range from 0 to 100, where higher values indicate 
better HRQoL. Anxiety and depression were measured 
by the Hospital anxiety and depression scale (HADS) 
[28]. The HADS consists of two subscales, one for anxi-
ety and one for depression, each comprising seven ques-
tions; each question scores 0–3 points and addition of the 
seven question scores yields the anxiety and depression 
subscale scores [28].
Fatigue was measured by the multiple sclerosis fatigue 
impact scale 5-Items Version (MFIS-5) [29]. Answers to 
each question are rated on a 5-point scale from 0 to 4; the 
MFIS-5 total score consists of the sum of the raw scores 
on these 5 items and ranges from 0 to 20, where higher 
scores indicate more experienced fatigue [29].
Ethical aspects
The study protocol was presented to the ethical review 
board “Medisch-Ethische Toetsing Onderzoek Patiënten” 
(METOPP), Tilburg, The Netherlands. Centrale commis-
sie mensgebonden onderzoek (CCMO) (Central Com-
mittee on Research Involving Human Subjects) number: 
NL36051.028.11 (http://www.ccmo.nl/en). The commit-
tee concluded that a review was not indicated, as the 
study did not qualify for being tested according to the 
Dutch Medical Research Involving Human Subjects Act 
of 1999 (http://www.wetten.overheid.nl/BWBR0009408) 
[30]. PwMS interested in participation were informed 
on the study and its procedures, had their questions 
answered, and underwent a screening interview and 
inclusion procedure. No incentives were offered. PwMS 
were included after they had given their written or online 
consent. The study was performed in agreement with 
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the Declaration of Helsinki (Ethical Principles for Medi-
cal Research Involving Human Subjects version 2013; 
64th World Medical Association General Assembly, For-
taleza, Brazil, October 2013) (www.wma.net) and the 
Wet medisch-wetenschappelijk onderzoek met mensen 
(WMO) (Dutch Medical Research Involving Human Sub-
jects Act) (www.wetten.overheid.nl/BWBR0009408).
Data analysis
For all outcomes the absolute values at baseline and at 
12 months after the Can Do treatment are described as 
mean with standard deviation (SD), and the percentage 
changes from baseline at 12  months are described as 
mean with standard error of the mean (SEM). Given the 
explorative nature of the study, we compared each out-
come with its baseline value by using a paired Student 
t-test. To evaluate the degree and clinical relevance of 
eventual changes we tested for each outcome the per-
centage change compared to baseline, instead of absolute 
values. Given the findings in the 6-month study, analyses 
were performed for RR and progressive groups separately 
[21]. For all tests a P < 0.05 was considered significant.
Results
Sixty PwMS were included in the study and completed 
the questionnaires at baseline. They received the Can 
Do treatment in March 2011, April 2011, February 2012, 
April 2012, June 2012 and August–September 2012; the 
1-, 3-, and 6-month data of the March 2011 and April 
2011 groups were included in the previous analysis [21]. 
Three PwMS did not complete the 3-day treatment and 
were therefore excluded from the analysis. Thirty-eight of 
the 57 PwMS completed the 12th month questionnaires 
(response rate 66.7 %), 25 females and 13 males; of these, 
22 had RRMS and 14 progressive MS, and in two the 
disease course was unknown. As a result there were 36 
analysable patients. In the first two groups (March 2011, 
April 2011) the baseline and 12th month assessments 
were performed via paper questionnaires, whereas in the 
other groups the baseline data were obtained via paper 
questionnaires and the 12th month data online.
The mean (SD) values at baseline and at 12  months, 
with the relative difference (percentage of baseline) 
and the P value for the comparison, for MSSES Func-
tion, MSSES Control, IPA Limitations, IPA Problems, 
MSQoL-54 Physical, MSQol-54 Mental, HADS Anxiety, 
HADS Depression and MFIS-5 scores in the RR group 
are presented in Table 1, and the corresponding values in 
the progressive group are presented in Table 2.
Twelve months after the Can Do treatment we 
observed that in the RR group, compared to baseline, 
self-efficacy control had increased by 20  % and physi-
cal HRQoL by almost 15  %, and that depression and 
anxiety had decreased by approximately 30 and 26  %, 
respectively. Moreover, the percentage changes in mental 
MSQoL-54 and MFIS-5 scores, and the corresponding P 
values suggested that mental HRQoL (+17 %) and fatigue 
(−20  %) might also have improved. In contrast, in the 
progressive group no changes suggestive of improvement 
were seen, neither with respect to P value, nor regarding 
the degree of change, except for the 25 % decrease in the 
depression score (P = 0.843).
Discussion
In this study we explored whether the Can Do treat-
ment, an intensive social cognitive treatment with sup-
port partners, might have long term beneficial effects in 
PwMS. We previously reported that 6 months after treat-
ment persons with RRMS showed a 25 % increase in self-
efficacy control and 22 and 18 % increases in mental and 
physical HRQoL, respectively. In line with these findings 
we now observed that in RRMS self-efficacy control and 
physical HRQoL had increased at 12  months compared 
to baseline by 20 and 15  %, respectively. With respect 
to progressive patients, the 6-month study showed no 
Table 1 Mean (standard deviation) values at  baseline 
and  12  months after  the Can Do treatment with  relative 
difference (percentage of  baseline) (mean, standard error 
of  the mean) and  P value for  comparison (paired t-test) 
for  self-efficacy [multiple sclerosis self-efficacy scale 
(MSSES)], impact on  participation and  autonomy [impact 
on  participation and  autonomy questionnaire (IPA)], 
HRQoL [multiple sclerosis quality of life-54 Items (MSQoL-
54)], anxiety and depression [Hospital anxiety and depres-
sion scale (HADS)], and  fatigue [modified fatigue impact 
scale-5 items (MFIS-5)] in  the relapsing remitting group 
(N = 22); Δ, difference
Relapsing remit-
ting group
Baseline 12th month % Δ P
MSSES function 
(N = 21)
80.86 (15.00) 79.58 (16.24) −0.68 (3.00) 0.708
MSSES control 
(N = 21)
57.68 (19.29) 64.02 (15.81) +20.21 (7.83) 0.012
IPA limitations 
(N = 22)
2.40 (0.60) 2.28 (0.60) −0.53 (7.41) 0.356
IPA problems 
(N = 20)
1.97 (0.37) 1.75 (0.51) −8.38 (5.51) 0.075
MSQoL‑54 physical 
(N = 11)
56.87 (11.93) 59.85 (18.68) +14.99 (7.09) 0.032
MSQoL‑54 mental 
(N = 17)
55.98 (11.82) 63.47 (14.12) +17.38 (8.16) 0.087
HADS anxiety 
(N = 22)
7.23 (3.45) 5.50 (3.16) −25.89 (8.64) 0.044
HADS depression 
(N = 22)
5.59 (3.62) 3.86 (3.23) −29.76 (14.53) 0.042
MFIS‑5 (N = 22) 12.09 (3.95) 9.95 (3.77) −19.82 (7.34) 0.080
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statistically significant changes in self-efficacy or HRQoL, 
nor in other outcomes. Likewise, in this 12-month study, 
changes suggestive of both statistical significance and 
clinical relevance were observed in not a single outcome 
in the progressive group.
Apart from the P values, the degree at which vari-
ous scores increased or decreased in the RRMS group, 
namely by 15–20 % or more, suggests that the 12-month 
changes may indeed have been clinically relevant and 
may have been experienced by the PwMS as such: having 
more confidence with managing symptoms and coping 
with the demands of their disease, having a better over-
all well-being, being less anxious, being less fatigued, and 
having a better mood.
We cannot explain the absence of improvements in 
progressive patients. However, based on the psychiatrist’s 
(RR) experience with patients with chronic diseases, like 
diabetes mellitus, we think that the resilience of progres-
sive MS patients is again and again tried by the continu-
ous increase in disabilities and limitations, and that this 
may result in a chronic mourning process. In contrast, 
RRMS patients are not constantly confronted with the 
consequences of their disease, since they not only experi-
ence recoveries from relapses but also stable periods in 
between relapses. As during the Can Do treatment no 
differences were observed by the multi-disciplinary team 
between relapsing–remitting and progressive patients, it 
might well be that progressive patients need long-term, 
low-intensity aftercare.
The major limitation of the study is that, given the 
uncontrolled design, no conclusion can be drawn about a 
causal relationship between the Can Do intervention and 
the observed changes. A confounding factor to be consid-
ered is a possible change in disease modifying treatment 
between baseline and the 12th month. For, in line with 
the underlying concept, the Can Do treatment may well 
have resulted in a higher assertiveness and a better com-
munication with the neurologist and nurse, leading to 
the start of (more potent) disease modifying treatment; it 
has been known that disease modifying treatments may 
increase HRQoL in RRMS [31]. This confounder cannot 
have been operative in the progressive group, as no such 
treatments are available for progressive MS.
Our study has several other limitations. Firstly, the 
number of patients is rather low, notably in the progres-
sive group. Nevertheless, there is a virtual absence of 
changes in the progressive group, both with respect to P 
values and percentage differences (except the depression 
score), and this contrasts with the findings in the RRMS 
group (seven out of nine P < 0.10; six out of nine differ-
ence ≥15  %), suggesting that indeed eventual beneficial 
effects of the treatment are limited to RRMS. Secondly, 
in the last four treatment groups the baseline data were 
acquired via the paper-and-pencil method, whereas the 
12th month data were obtained online. We think that this 
methodological inconsistency had no major impact on 
the outcomes, as it has been reported that the quality of 
web-based data acquisition is equivalent to that of con-
ventional methods [32]. Thirdly, although the 12-month 
response rate was reasonable, it may well be that those 
PwMS who were disappointed due to a lack of improve-
ment have preferentially not completed the follow-up 
questionnaires.
In all, this study suggests that the intensive social cog-
nitive Can Do treatment with participation of support 
partners might have long lasting beneficial effects on 
control self-efficacy and HRQoL in persons with RRMS. 
The findings seem to confirm our choice to perform a 
randomized controlled trial on the effectiveness of the 
Can Do treatment specifically in persons with the RR 
type of disease [33]. This trial is ongoing.
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MFIS‑5 (N = 14) 12.57 (4.03) 11.93 (3.36) −1.00 (6.60) 0.395
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participation and autonomy; METOPP: medisch‑ethische toetsing onderzoek 
patiënten; MFIS‑5: multiple sclerosis fatigue impact scale 5‑items; MS: multiple 
sclerosis; MSQoL‑54: multiple sclerosis quality of life 54‑items; MSSES: multiple 
sclerosis self‑efficacy scale; PwMS: persons with multiple sclerosis; RR: relaps‑
ing remitting; RRMS: relapsing remitting multiple sclerosis; P: probability; 
SD: standard deviation; SEM: standard error of the mean; VPN: virtual private 
network; WMO: wet medisch‑wetenschappelijk onderzoek met mensen.
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